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Summary
Purpose: Risk of depression, anxiety, and reduced quality of life is elevated in epilepsy
patients, due to a range of factors including aetiology, structural brain lesions, seizure
worry, epilepsy surgery, hereditary factors, psychosocial factors, and possible adverse
effects of antiepileptic drugs (AEDs). Studies on the relationships between epilepsy-
related variables and behavioural adjustment have been mainly conducted on patients
with persisting seizures,whereas the present study investigated behavioural function in
epilepsy patients seizure-free for more than 2 years on monotherapy.
Methods: Adults with epilepsy on AED monotherapy and without epileptic seizures for
at least 2 years (n = 126) were assessed with the Minnesota Multiphasic Personality
Inventory-2 (MMPI-2), in addition to MRI and EEG.
Results: Group analysis foundmean MMPI-2 scores on all the clinical and content scales
to be within the normal range. Abnormally elevated scores on scales measuring aspects
of depression, health-related concerns, low self-esteem, negative treatment indica-
tors, and physical complaints were recorded in a higher proportion of patients than
would normally be expected. Multiple regression analysis showed that MRI pathology
was a significant predictor for an abnormally poor score on the low self-esteem scale,
and that epilepsy onset18 years was a significant predictor of abnormally poor score
on the work interference scale.
Discussion: Although most seizure-free epilepsy patients show normal behavioural
adjustment, a higher proportion than expected obtained scores suggesting depression,
low self-esteem, and health-related concerns. Both neurobiological and psychosocial
factors may explain different aspects of problems with behavioural adjustment.
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +47 92097373; fax: +47 22921783.
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Behavioural adjustment problems in epilepsy, with
focus on depression, anxiety, quality of life (QOL),
and stigma, have been highlighted in numerous
studies. Recent studies confirm a moderate to high
frequency of depression (ranging between 19 and
60%) in patients with epilepsy.1—4 The rate of mood
disorders in epilepsy has been reported to be higher
than in other medical conditions, such as diabetes
and asthma.5 Among the most important risk factors
for depression in patients with epilepsy are: com-
plex partial seizures, absence of secondary general-
ized tonic—clonic seizures (GTCS), drug resistance,
lack of occupational activity,4 epileptic focus in the
temporal lobe of the dominant hemisphere and
neuropsychological evidence of frontal lobe dys-
function,31,32 negative impact of anticonvulsant
drugs,10,34,40 and psychosocial factors.35 The pre-
valence of anxiety disorders in epilepsy has been
found to be as high as that of mood disorders, or
even higher. Swinkels et al.1 reported a prevalence
of anxiety disorders in epilepsy patients of 25%, and
19% for mood disorders, and in specialist settings,
the occurrence of anxiety disorders may exceed
50%.6,7 Seizure frequency has been linked with
severity of anxiety in some studies,41 and the risk
of anxiety seems to be higher in focal epilepsies than
general epilepsies.42 Some groups have found an
association with left temporal lobe involvement.44
The highest frequency of psychopathology, including
both anxiety and depression, is found in patients
with persistent refractory epilepsy.2,45,46 In patients
with refractory epilepsy, symptoms of depression
and seizure worry have been found to be the most
important factors affecting QOL.8 Another major
problem for epilepsy patients is stigmatisation,
which is reported to be experienced by approxi-
mately 50%, and have been correlated with feelings
of anxiety, depression and also long-term health
problems, injuries and reported side-effects of anti-
epileptic drugs (AEDs).9
Approximately 70% of patients with recent onset
epilepsy become seizure-free, either without med-
ication or on AEDs.13,14 Most studies of behavioural
adjustment and QOL have been conducted on
patients with active epilepsy (continuing to experi-
ence seizures), and relatively few studies have
investigated these phenomena in patients with
well-controlled epilepsy. Engelberts et al.11 found
that patients with localization-related epilepsy,
well-controlled on carbamazepine monotherapy,
had unimpaired health-related QOL in comparison
with controls matched by age, gender, and educa-
tion. Uijl et al.12 conducted a cross-sectional study
of subjective complaints in epilepsy patients whosesymptoms were well-controlled with AED monother-
apy (85%), or polytherapy (15%). QOL was measured
by questionnaire (Qoilie-10) and personality traits
by Symptom Checklist 90 (SCL-90). Moderate to
severe subjective complaints were reported by
67% of these patients on the Qoilie-10 question-
naire. Cognitive complaints were most common,
and were primarily associated with AED polyther-
apy, and high scores on psycho-neuroticism on the
SCL-90.
To our knowledge, previous studies have not
focused on entirely seizure-free epilepsy patients.
Thus, the aim of this study was to describe beha-
vioural function in such a group, and to analyse
possible predictors for problems with behavioural
adjustment, including age at epilepsy onset, seizure
variety, duration of seizure freedom, EEG-findings,
MRI pathology, and AED treatment. A subgroup of
patients with idiopathic generalized epilepsy (IGE)
was described separately; as these have no con-
founding variables from cerebral lesions and thus
may be a good model for studying the effect of
epilepsy on behavioural function.
Based on the good cognitive outcome results
reported in the study by Hessen et al.,15 which
included the same group of seizure-free epilepsy
patients as participated in the present study, our
main hypothesis was that this group, unlike patients
with active epilepsy, would show behavioural
adjustments similar to those observed in the general
population.Methods
Selection of patients–—inclusion/exclusion
criteria
The patients described in the present paper were
participants in a large study investigating the with-
drawal of AEDs in seizure-free epilepsy patients on
monotherapy. They were selected on basis of clin-
ical criteria from the epilepsy registry at the Aker-
shus University Hospital and from six neurological
outpatient clinics in the Oslo area: They should have
a diagnosis of epilepsy (at least two unprovoked
seizures), be between 18 and 67 years old and
seizure-free on monotherapy for at least 2 years
at the time of inclusion. Excluded were patients
with the following characteristics: juvenile myoclo-
nus epilepsy (JME), poly-pharmacy, paroxysmal epi-
leptiform activity in patients with primarily
generalized epilepsy, mental retardation, two prior
withdrawal attempts, pregnant or seeking preg-
nancy, progressive neurological disease, other ser-
ious disease which may influence the health status
424 E. Hessen et al.of the patient in the study period and co-medication
(except post menopausal hormone substitution,
antihypertensive, ASA and thyroxin).
Initially, 241 patients seemed to fulfil the inclu-
sion criteria, and were invited to participate in the
study. Of these patients, 17 (7%) did not respond to
the invitation, 32 (13%) declined to participate, 13
(5%) still had seizures, 20 (8%) fulfilled other exclu-
sion criteria, and 1 had an acute disease. Thus, of
the initial 241 patients, 83 (34%) were not eligible or
did not wish to participate. The relatively large
number of patients that did not wish to participate
(32) must be viewed against the background that
this study was part of a larger study of AED with-
drawal in seizure-free epilepsy patients on mono-
therapy. Therefore, the patients that declined to
participate, primarily did so due to fear of seizure
relapse and the potential consequences of seizure
relapse (e.g. loss of driver’s license). Of the remain-
ing 158 patients, 126 (80%) agreed to answer the
Minnesota Multiphasic Personality Inventory-2
(MMPI-2) and were included in the present study.
Behavioural assessment
Behavioural function was evaluated with The Nor-
wegian Edition of MMPI-2.16,18 Norwegian normative
data were used to score data from the MMPI-2.18 All
test results were converted to T-scores, a normallyTable 1 Demographic and clinical characteristics of study
Demographic and clinical variables All study p
(n = 126)
Mean age (S.D.) 39 (11.9)
Female (%) 67 (53)
Education years (S.D.) 13.2 (2.8
Work (%) 123 (98)
Retirement/disability benefit (%) 3 (2)
Epilepsy onset 18 years (%) 43 (34)
Seizure-free >5 years (%) 83 (66)
Duration of seizure freedom years (S.D.) 9.8 (3.8
Partial seizures (%) 91 (72)
Generalized seizures (%) 34 (27)
Idiopathic generalized epilepsy (%) 24 (19)
Presence of GTCS (%) 30 (24)
Unclassified seizures 1 (1)
Known etiology (%) 33 (26)
MRI pathology (1 tesla) (%) 29 (24)
Normal neurological status (%) 117 (93)
Carbamazepine (%) 80 (63)
Valproate (%) 25 (20)
Phenytoin (%) 12 (10)
Phenobarbital (%) 3 (2)
Lamotrigine (%) 6 (5)
Epileptiform activity on the EEG (%) 51 (41)
AED within therapeutic range (%) 99 (79)distributed scale with a mean score of 50 and stan-
dard deviation (S.D.) of 10. Both the 10 standard
clinical scales and the 15 content scales from the
MMPI-216 were used as outcome measures. Defini-
tion of abnormal function was T-scores equal to or
greater than 65 on the different subscales.
Statistical analysis
Statistical analyses were performed with the Sta-
tistical Package for Social Sciences for Windows
(SPSS, version 12.0). First, descriptive statistics of
the demographic, clinical and behavioural charac-
teristics of the patient population were computed.
Odds ratios for occurrence of abnormal scores on the
MMPI-2 were estimated with logistic regression ana-
lysis. To assess possible predictors for abnormal
scores, variables of importance were tested first
in a logistic univariate model, and then in a multi-
variate logistic model. Behavioural adjustment was
dichotomised, with the categories normal and
abnormal as the dependent variable. A series of
independent t-tests were then performed compar-
ing behavioural function between subgroups of
patients defined by clinical variables. As the
MMPI-2 subtests are not independent, a Bonferroni
correction was not considered appropriate, as this
method is highly conservative and has the potential
to miss real differences between the groups.19patients
atients Patients without
IGE (n = 102)
Patients with
IGE (n = 24)
39 (11.6) 38 (13.2)
55 (54) 12 (50)
) 13.2 (2.8) 13.2 (2.9)
99 (97) 24 (100)
3 (3) 0
36 (35) 7 (29)
65 (64) 18 (75)
) 10.0 (4.2) 9.8 (3.7)
91 (89) 0
10 (10) 24 (100)
0 24 (100)
9 (9) 21 (88)
1 (1) 0
33 (32) 0
23 (23) 6 (26)
95 (93) 22 (92)
67 (66) 13 (54)
18 (18) 7 (29)
9 (9) 3 (13)
2 (2) 1 (4)
6 (6) 0
41 (41) 10 (42)
81 (80) 18 (75)
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Demographic and clinical characteristics
Demographic data and clinical information of the
126 study patients are presented in Table 1. The
demographic characteristics of patients with and
without IGE were similar. There were no demo-
graphic differences between the 158 patients
included in our study of cognitive function in sei-
zure-free epilepsy patients15 and the 126 patients in
the present study. Cognitive function was also simi-
lar between these two groups of study patients, with
the exception of somewhat poorer scores from the
patients participating in this study in two tests:
delayed visual memory20: T = 49.0 versus T = 53.0
( p = 0.016), and COWA (word fluency)21: T = 38.5
versus T = 43.0 ( p = 0.020).
Differences in the groups with and without IGE
regarding seizure characteristics, aetiology, and
medication are shown in Table 1. Apart from these
differences, the IGE and non-IGE groups were simi-Table 2 Mean (S.D.) MMPI-2 T-scores for all study patients
All study patien
(S.D.) n = 126
Clinical scales
L 56.6 11.0)
F 55.4 (12.2)
K 49.3 (11.4)
Hypochondriasis (Hs) 58.0 (11.9)
Depression (D) 59.0 (12.3)
Hysteria (Hy) 54.7 (11.4)
Psychopathic deviate (Pd) 48.4 (10.0)
Masculinity—Femininity (Mf) 49.0 (10.0)
Paranoia (Pa) 50.1 (10.2)
Psychastenia (Pt) 53.7 (11.6)
Schizophrenia (Sc) 54.3 (12.0)
Hypomania (Ma) 50.3 (10.5)
Social introversion (SI) 54.8 (11.8)
Content scales
Anxiety (ANX) 52.8 (12.1)
Fears (FRS) 51.2 (11.6)
Obsessions (OBS) 51.1 (11.3)
Depression (DEP) 53.7 (12.7)
Health concerns (HEA) 58.7 (12.6)
Bizarre Mentation (BIZ) 50.3 (10.7)
Anger (ANG) 48.3 (9.7)
Cynicism (CYN) 51.1 (11.4)
Antisocial practices (ASP) 50.8 (10.2)
Type A (TPA) 47.6 (11.6)
Low self-esteem (LSE) 55.8 (14.3)
Social discomfort (SOD) 52.7 (11.6)
Family problems (FAM) 49.5 (12.3)
Work interference (WRK) 53.3 (13.7)
Negative treatment indicators (TRT) 55.5 (15.3)
p < 0.05.lar, with regard to seizure debut, duration of seizure
freedom, epileptiform EEG activity, and AEDs within
therapeutic range. The positive MRI-findings in the
IGE group were unspecific and not related to the
epilepsy.
Behavioural function
Information about behavioural function in the total
patient group, and in the groups with and without
IGE, is given Table 2. Profiles of the clinical scales
and the content scales for the whole group are
shown in Figs. 1 and 2.
Scores on all the clinical scales and content scales
were within the normal range. The scores were close
to one standard deviation above the normative
mean on the hypochondriasis (Hs) scale (all
patients: T = 58.0, without IGE: T = 58.4, IGE:
T = 56.2), on the depression (D) scale (all patients:
T = 59.0, without IGE: T = 59.2, IGE: T = 58.0) and on
the health concerns (HEA) scale (all patients:
T = 58.7, without IGE: T = 59.2, IGE: T = 56.3). Onand for patients with and without IGE
ts Patients without
IGE (S.D.) n = 102
Patients with
IGE (S.D.) n = 24
56.4 (11.2) 57.3 (10.7) n.s.
55.7 (12.1) 54.3 (12.5) n.s.
49.1 (11.2) 50.1 (12.4) n.s
58.4 (12.5) 56.2 (10.7) n.s.
59.2 (12.4) 58.0 (12.2) n.s.
54.7 (11.8) 54.7 (9.6) n.s.
48.5 (10.0) 48.3 (10.0) n.s.
48.9 (10.1) 49.2 (9.7) n.s.
50.2 (10.4) 49.4 (9.5) n.s.
54.4 (11.5) 50.9 (12.0) n.s.
54.6 (11.5) 53.0 (14.2) n.s.
50.1 (10.6) 51.2 (10.1) n.s.
55.6 (12.2) 51.4 (9.5) n.s.
53.2 (11.8) 51.3 (13.3) n.s
51.2 (11.5) 51.3 (12.1) n.s.
51.4 (11.1) 49.6 (11.9) n.s.
53.7 (12.8) 53.8 (12.5) n.s.
59.2 (12.7) 56.3 (12.0) n.s.
50.6 (10.9) 49.2 (10.1) n.s
48.3 (9.6) 48.3 (10.5) n.s
51.4 (11.8) 50.3 (9.9) n.s
51.2 (10.3) 49.0 (9.5) n.s
48.1 (10.6) 45.3 (15.2) n.s
56.1 (14.4) 54.6 (13.9) n.s.
53.3 (12.2) 50.3 (8.9) n.s.
49.2 (12.1) 50.9 (13.0) n.s.
53.6 (13.2) 52.0 (15.7) n.s.
55.8 (15.0) 54.1 (16.6) n.s.
426 E. Hessen et al.
Figure 1 MMPI-2 mean T-scores, clinical scales. Figure 2 MMPI-2 mean T-scores, content scales.the other scales, the scores were close to the
normative mean. On several of the scales, the
percentage of patients with T-scores in the patho-
logical range (T  65) were rather high, compared
with the expected 7% in the normative group
(Table 3): 33% for the D scale, 29% for the HEA scale,Table 3 Frequency of T-scores 65 (abnormal function) in
without IGE
All study pa
(S.D.) n = 1
Clinical scales
L n (%) 34 (27)
F n (%) 22 (18)
K n (%) 11 (9)
Hypochondriasis (Hs) n (%) 30 (24)
Depression (D) n (%) 41 (33)
Hysteria (Hy) n (%) 26 (21)
Psychopathic deviate (Pd) n (%) 9 (7)
Masculinity—Femininity (Mf) n (%) 9 (7)
Paranoia (Pa) n (%) 10 (8)
Psychastenia (Pt) n (%) 23 (18)
Schizophrenia (Sc) n (%) 25 (20)
Hypomania (Ma) n (%) 17 (14)
Social introversion (SI) n (%) 21 (17)
Content scales
Anxiety (ANX) n (%) 18 (14)
Fears (FRS) n (%) 18 (14)
Obsessions (OBS) n (%) 14 (11)
Depression (DEP) n (%) 24 (19)
Health concerns (HEA) n (%) 36 (29)
Bizarre mentation (BIZ) n (%) 14 (11)
Anger (ANG) n (%) 7 (6)
Cynicism (CYN) n (%) 18 (14)
Antisocial practices (ASP) n (%) 13 (10)
Type A (TPA) n (%) 8 (6)
Low self-esteem (LSE) n (%) 31 (25)
Social discomfort (SOD) n (%) 23 (18)
Family problems (FAM) n (%) 16 (13)
Work interference (WRK) n (%) 24 (19)
Negative treatment indicators (TRT) n (%) 30 (24)
p < 0.05.25% for the low self-esteem (LSE), 24% for the
negative treatment indicators (TRT) scale, and
24% for the Hs scale. In addition, 27% of the patients
scored T  65 on the L scale. There were no sig-
nificant differences between the non-IGE and the
IGE group.the total patient sample and for patients with IGE and
tients
26
Patients without
IGE (S.D.) n = 102
Patients with
IGE (S.D.) n = 24
27 (27) 7 (29) n.s.
19 (19) 3 (13) n.s.
8 (8) 3 (13) n.s
25 (25) 5 (21) n.s.
33 (32) 8 (33) n.s.
19 (19) 7 (29) n.s.
8 (8) 1 (4) n.s.
8 (8) 1 (4) n.s.
8 (8) 2 (8) n.s.
20 (20) 3 (13) n.s.
19 (19) 6 (25) n.s.
14 (14) 3 (13) n.s.
18 (18) 3 (13) n.s.
13 (13) 5 (21) n.s
15 (15) 3 (13) n.s.
12 (12) 2 (8) n.s.
19 (18) 5 (21) n.s.
31 (30) 5 (21) n.s.
12 (12) 2 (8) n.s
5 (5) 2 (8) n.s
16 (16) 2 (8) n.s
11 (11) 2 (8) n.s
6 (6) 2 (8) n.s
26 (26) 5 (21) n.s.
21 (21) 2 (8) n.s.
11 (11) 5 (21) n.s.
21 (21)) 3 (13) n.s.
24 (24) 6 (25) n.s.
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Table 4 Predictors of behavioural disturbance in epilepsy patients seizure-free for more than 2 years on mono-
therapy
Variable Univariate analysis Multivariate analysis
OR p OR 95% CI p
Low self-esteem (LSE) T-score 65
MRI pathology 1.20 0.004 1.20 1.05—1.36 0.008
Epileptiform activity on EEG 1.90 0.11 1.65 0.75—3.64 0.22
Epilepsy onset 18 years 1.87 0.14 2.01 0.78—5.22 0.15
Presence of GTCS 0.54 0.25 0.62 0.19—2.06 0.43
AED within therapeutic range 1.25 0.34
Complex partial seizure 1.41 0.45
Idiopathic generalized epilepsy 0.77 0.63
Duration of seizure freedom >5 years 1.08 0.86
Work interference (WRK) T-score 65
Epilepsy onset 18 years 2.84 0.025 3.35 1.20—9.33 0.021
MRI pathology 1.13 0.06 1.13 0.98—1.30 0.09
Epileptiform activity on EEG 1.67 0.14 1.12 0.45—2.78 0.81
AED within therapeutic range 1.16 0.19 1.49 0.53—4.21 0.45
Duration of seizure freedom >5 years 0.65 0.35
Idiopathic generalized epilepsy 0.55 0.37
Complex partial seizure 1.54 0.42
Presence of GTCS 0.81 0.70Prediction of abnormally elevated
scores on the LSE and work
interference (WRK) scales in the total
patient sample and for patients with
and without IGE
Variables of importance were tested in a logistic
univariatemodel. T-score65 for all the clinical and
content scales were entered individually as depen-
dent variables. The independent variables included
MRI pathology, epileptiform activity on EEG, pre-
sence of GTCS, presence of IGE, complex partial
seizures, epilepsy onset at age <18 years, duration
of seizure freedom >5 years, and AED within ther-
apeutic range. Significant predictors for abnormally
elevated scores were only demonstrated for the
total patient sample, on two of the dependent
variables (Table 4). Multiple regression analysis
showed that MRI pathology was a significant pre-
dictor for abnormally poor score on the LSE scale
(OR = 1.20, p = 0.008), and that epilepsy onset 18
years was a significant predictor of abnormally poor
score on the WRK scale (OR = 3.35, p = 0.021).Discussion
The main findings of the present study were as
follows:(1) The mean scores on the clinical and content
scales were within the normal range.(2) The subscales Hs, D and HEA had group scores
close to one standard deviation above the nor-
mative mean.(3) Contrary to that which was expected, the per-
centage of patients with abnormally elevated
scores (T  65) were considerably higher than in
the normative group being 33% for the D scale,
29% for the HEA scale, 25% for the LSE, 24% for
the TRT and 24% for the Hs scale, as compared
with 7% in normative group.(4) Multiple regression analysis showed that MRI
pathology was a significant predictor for abnor-
mally poor score on the LSE scale and that
epilepsy onset 18 years was a significant pre-
dictor of abnormally poor score on the WRK
scale.(5) A large group of epilepsy patients, who had been
seizure-free for a minimum of 2 years, had
average durations of education and employment
status similar to those of the population mean.To our knowledge previous studies of behavioural
adjustment in epilepsy have not focused on exclu-
sively seizure-free patients. Our study included suf-
ficient patients (n = 126) to enable statistically valid
investigation of relationships between medical vari-
ables of importance and behavioural function.
The results are relevant for patients that fulfilled
the inclusion criteria. There is reason to believe that
the patients participating in this study are repre-
sentative of the majority of seizure-free epilepsy
patients,13,17 however, the findings are not valid for
all seizure-free epilepsy patients, as persons with
428 E. Hessen et al.poly-pharmacy,22 paroxysmal epileptiform activity
with primarily generalized epilepsy,23 mental retar-
dation, and progressive neurological disease were
excluded from the study.
There has been some contention regarding the
validity of MMPI and MMPI-2 in detecting abnormal
behaviour in patients with epilepsy. The concern is
that patients with epilepsy may have falsely exag-
gerated MMPI-2 scale scores, due to endorsement of
disease-related items. Thus, Nelson et al.24 suggest
cautious interpretation of standard MMPI-2 scores in
patients with epilepsy, based on a study of patients
with mainly intractable epilepsy. Dikmen et al.25
however, found that MMPI is sensitive to behavioural
abnormalities in patients with different seizure
categories. A study by Modrego et al.26 also supports
the validity of MMPI for detection of abnormal
behaviour in patients with chronic non-lesional epi-
lepsy. Compared with the Diagnostic and Statistical
Manual of Mental Disorders-Version Four (DSM-IV)
criteria, the MMPI correctly identified personality
disorders, especially depression and paranoid per-
sonality. In an overview of behavioural and cognitive
assessments in clinical trials of AEDs, Baker and
Marson27 reported that the MMPI was the most
commonly used test of behavioural function, and
was able to detect changes in more than half of the
trials in which it was used. This represents a higher
degree of sensitivity than other behavioural meth-
ods that have been utilised in clinical trials. Ques-
tioning the validity of MMPI-2 in studies of persons
with intractable epilepsy or ongoing seizure activity
is somewhat irrelevant in the context of this study,
as all the patients were seizure-free.
A relatively large proportion of the patients had
elevated score (T  65) on the L scale. Scores in this
range can be typical for persons who lack insight into
their own behaviour, who deny common human
faults, or who are trying to create a favourable
impression of themselves. Thus, the rather high
frequency of elevated L scores may suggest under-
reporting of problems in the present group of
patients. However, the group with T-scores 65
on the L scale (n = 34) and the group with T-scores
<65 (n = 92), had similar scores on 9 of the 10
clinical subscales. Significantly lower scores for
patients with an elevated L score was only evident
on the social introversion (SI) scale, T = 50.4 versus
T = 56.5 (p = 0.009). Consequently, there seems to
be no indication that the high occurrence of ele-
vated L scores caused significantly changed scores
on the MMPI-2.
On the basis of Norwegian normative data, the
mean T-scores for all the clinical and content scales
on MMPI-2 were within the normal range. The sub-
scales Hs, D, and HEA had mean scores close to onestandard deviation above the normative mean, and
the proportion of patients with abnormally elevated
scores (T  65) were considerably above the propor-
tion expected based on the normative group.
Patients with T-score 65 on the D scale typically
exhibit a depressed mood. Patients with scores in
the same range on the HS scale are described as
excessively concerned about vague physical symp-
toms, while patients with similar HEA scores are
worried about their health, especially with regard to
physical symptoms. Abnormally elevated scores on
the LSE scale are associated with poor self-esteem,
and similar scores on the TRT scale are typical for
persons with a negative or pessimistic outlook on
treatment possibilities.28 The high frequency of
abnormally elevated scores on these, and other,
subscales (Table 3) was contrary to expected as
based upon the good cognitive outcomes obtained
in our previous study of the same patients.15 The
results of the present study may resemble those
from studies of patients with active epilepsy, that
find moderate to high frequency of depression,1—4
seizure worry and reduced QOL,8 and anxiety.1,6,7
The average duration of education of the patient
group was similar to the population mean in Norway,
for persons between 30 and 39 years, and 2% of the
patients were either receiving disability benefit or
had retired, which is less than the expected 6% for a
similar age group in Norway.29 The groups of patients
with IGE and the heterogeneous group without IGE
had similar education durations and work status.
Although all the mean MMPI-2 scores in this study
were within the normal range, the frequency of
patients with abnormally elevated scores on several
depression-related subscales, were clearly above
expected, based on normative data. The literature
suggests that neurobiological,4,30,31,32 iatro-
genic,10,34,40 and psychosocial4,35 dimensions con-
stitute main risk factors for depression in epilepsy.
Although the present study does not provide any
clear answers regarding risk factors for depression in
seizure-free epilepsy patients, the results may indi-
cate some possible clues.
With regard to neurobiological risk factors,
depression appears to be elevated in patients with
seizures of left temporal lobe origin and with neu-
rophysiological and neuropsychological evidence of
frontal lobe dysregulation.31,32 However, the theory
of left-sided involvement has been challenged by
Quiske et al.,33 who found a similar predominance of
depressive symptoms in both left and right-sides
pathologies. The patients in the present study had
been seizure-free for 2 years or more, and were
therefore not directly comparable with patients in
those studies with patients with persistent seizures
and verified neurophysiological and neuropsycholo-
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pathology was a significant predictor for abnormally
poor score on the LSE scale does suggest that a
depression-related phenomenon, like low self-
esteem, may be associated with neurobiological
factors in seizure-free epilepsy patients also.
With regard to iatrogenic risk factors for depres-
sion, the relationship between AEDs and mood have
been discussed, and particularly that phenobarbital
has been associated with increased risk of depression
in comparison with carbamazepine.34 In the present
study most of the patients were treated with carba-
mazepine, and only 3 patients received phenobarbi-
tal. In the randomised, double-blinded, and placebo-
controlledwithdrawal study byHessen et al.,10 based
on the same group of patients as in this study, only
slightly elevated depression scores were related to
the use of AEDs. On the depression scale (DEP) with-
drawal resulted in an improvement of 4.1 T-scores
(p = 0.012). Therefore, it is probable that treatment
with AEDs contributes slightly to the high frequency
of depressed patients, but it seems unlikely that AED
treatment alone can explain these results.
With regard to psychosocial risk factors for depres-
sion in epilepsy a themeassociatedwith the nature of
epilepsy has been discussed in the literature. It
involves the fact that patients with epilepsy experi-
ence random seizures over which they have minimal
control. This has been discussed in the context of the
concepts of external locus of control and the concept
of learnedhelplessness, andhavebeen found toapply
to the epilepsy—depression relation.35,36 Also the
perception of stigma, which affects approximately
50%ofpeoplewith epilepsy9 havebeen shown tohave
a positive relationship with affective disorders.36
Although the present seizure-free patients probably
have less seizure worry, less feeling of external locus
of control, and less experience of stigma than
patients with persistent seizures, it is probable that
these psychosocial elements also have influence on
these patients and the rather high frequency of
depressive symptoms and health-related concerns.
This may be particularly relevant in the study
patients that were included in a trial with the aim
to withdraw their medication. This is a sensitive
situation which may have contributed to the level
of seizure worry and health-related concerns.
Early epilepsy onset (18 years) was significantly
associated with abnormally poor score on the WRK
scale. Scores in this range are typical for persons
who report impaired working ability, poor self-con-
fidence, lack of energy, and a tendency to give up
easily when facing a problem.28 It is difficult to
explain this finding, and both neurobiological and
psychosocial factors may be of relevance. Studies
have indicated interruption of brain maturation inepilepsy with seizure debut in childhood.37,39 In
addition, adverse psychosocial experiences related
to seizures and seizure worry during childhood and
adolescence may have a negative influence on the
development of self-confidence.Conclusions
Group analysis of epilepsy patients, seizure-free for
more than 2 years, found mean MMPI-2 scores within
the normal range, and in addition an average dura-
tion of education and employment status similar to
the population mean. Contrary to expected, the
proportion of patients with abnormally elevated
scores on scales measuring aspects of depression,
health-related concerns, low self-esteem, negative
treatment indicators, and physical complaints were
clearly above that which would normally be
expected. Multiple regression analysis showed that
MRI pathology was a significant predictor for an
abnormally poor score on the low self-esteem scale,
and that epilepsy onset 18 years was a significant
predictor of an abnormally poor score on the work
interference scale.Conflict of interest
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